29 April 2008
Changes in drug prescription utilization for diabetic and hypertensive outpatients after initiation of the National Health Insurance's Global Budget Program in Taiwan
Chih-Chieh ChouACDEFG, Kun-Yi HuDEF, Ni-Ren WuBCD, Yeong-Huang ChengD, Ching-Hui LohD, Ming-Kung YehADEFGMed Sci Monit 2008; 14(5): PH33-39 :: ID: 855740
Abstract
Background
To examine changes in medicine utilization and prescription trends for diabetic (DM) and hypertensive (HT) patients upon initiation of the National Health Insurance (NHI) global budget (GB) program in Taiwan.
Material and Method
Data on hospital-based outpatient prescriptions for DM and HT from the Taipei branch before and after the GB were analyzed from January 2002 to December 2004. A secondary analysis of reimbursed data, with descriptive and trend analyses of the four indicators, daily oral medication cost, daily tablets used, medicine items per prescription, and tablet cost, was conducted.
Results
The comparisons of before and after the GB were as follows: Daily oral medication cost increased from US $0.585 to $0.956 (64%) for the DM group and from $1.01 to $1.07 (6.12%) for the HT group. The increments for daily used tablets, medicine items per prescription, and tablet cost were 33.3%, 17.9%, and 26.5% for the DM group and 6.65%, 3.31%, and 0.27% for the HT group. Indicators for the DM group not only increased significantly compared with those of the HT group, but also had higher adjusted beta coefficients. The comparisons of before and after the GB showed that the increments for the DM group decreased slightly, but not those for the HT group.
Conclusions
The indicators for DM were significantly higher than those of HT group during the implementation phase of the GB. The GB program implemented by the NHI in Taiwan slightly slowed the trend of hospital-based ambulatory prescription costs of DM, but not HT.
Keywords: State Medicine, Taiwan, Hypoglycemic Agents - pharmacology, Hypertension - economics, Health Expenditures - trends, Drug Costs, Diabetes Mellitus - economics, Child, Antihypertensive Agents - economics, Aged, 80 and over, Adolescent
Editorial
01 March 2025 : Editorial
Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical TrialsDOI: 10.12659/MSM.948672
Med Sci Monit 2025; 31:e948672
In Press
Clinical Research
Inflammatory Biomarkers in Smokers: Implications for Ligamentum Flavum HypertrophyMed Sci Monit In Press; DOI: 10.12659/MSM.947508
Clinical Research
Balancing Image Quality and Iodine Intake: Insights from CT Spectral Imaging of the Portal VeinMed Sci Monit In Press; DOI: 10.12659/MSM.947391
Review article
Regulatory Efforts and Health Implications of Energy Drink Consumption by Minors in PolandMed Sci Monit In Press; DOI: 10.12659/MSM.947124
Review article
Current Trends and Innovations in Oral and Maxillofacial ReconstructionMed Sci Monit In Press; DOI: 10.12659/MSM.947152
Most Viewed Current Articles
17 Jan 2024 : Review article 7,216,875
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,406
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 27,844
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 22,117
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912